Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.
Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.
Mol Ther. 2018 Jun 6;26(6):1414-1422. doi: 10.1016/j.ymthe.2018.04.001. Epub 2018 Apr 5.
Over the last 60 years an eclectic collection of microbes has been tested in a variety of pre-clinical models as anti-cancer agents. At the forefront of this research are a number of virus-based platforms that have shown exciting activity in a variety of pre-clinical models and are collectively referred to as oncolytic viruses. Our true understanding of the potential and limitations of this therapeutic modality has been substantially advanced through clinical studies carried out over the last 25 years. Perhaps not surprising, as with all other cancer therapeutics, it has become clear that current oncolytic virus therapeutics on their own are unlikely to be effective in the majority of patients. The greatest therapeutic gains will therefore be made through thoughtful combination strategies built upon an understanding of cancer biology.
在过去的 60 年中，各种各样的微生物被作为抗癌药物在各种临床前模型中进行测试。在这一研究领域的前沿是一些基于病毒的平台，它们在多种临床前模型中表现出了令人兴奋的活性，被统称为溶瘤病毒。通过过去 25 年进行的临床研究，我们对这种治疗方式的潜力和局限性有了更深入的了解。也许并不奇怪，与所有其他癌症治疗方法一样，目前溶瘤病毒疗法本身在大多数患者中不太可能有效。因此，通过基于对癌症生物学理解的深思熟虑的组合策略，将会取得最大的治疗效果。
